CLEAN CELLS INVESTS OVER €13M IN NEW BIOPHARMACEUTICAL PRODUCTION SITE
5,300 m2 new facility will quadruple analysis and production capacity, becoming largest site in Europe for biopharmaceuticals quality control services... View Article
Xenothera signs a memorandum of understanding with the Vietnamese conglomerate Vingroup
Following discussions held under the authority of the Vietnamese Minister of Health, Trân Van Thuân, the Nantes-based company XENOTHERA, which... View Article
Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 Vaccine
Valneva, a specialty vaccine company, today announced that it has completed recruitment of the initial cohort of elderly participants in... View Article
New member | ClinGroup
ClinGroup is a full CRO of 6 Business Units providing Comprehensive Solutions For Health industry R&D; Established since 2002& Expanding... View Article
New member | My-Serious-Game
Founded in 2014, My-Serious-Game is the French leader in custom-built digital learning solutions and a key European player: from analyzing... View Article
OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®
Further Strengthens Global Intellectual Property Portfolio for Tedopi® in Non-Small Cell Lung Cancer until 2035 OSE Immunotherapeutics announced today that... View Article
Valneva: U.S. DoD Exercises First Year Option on IXIARO® Supply Contract
Valneva, a specialty vaccine company, today announced that the U.S. Department of Defense (DoD) has exercised the first option of... View Article
New member | Centaur Clinical
Centaur Clinical (CC) is a CRO created in 2016 that conducts pre-clinical assays and clinical studies in Europe directly or... View Article
OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer
Clinical trial sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp & Dohme Corp.... View Article
Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome
Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics, a French biotech, have announced enrollment of the first patient... View Article